Oruka Therapeutics, Inc.
ORKA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $28,988 | $24,087 | $19,925 | $32,327 |
| G&A Expenses | $5,117 | $4,342 | $5,161 | $5,675 |
| SG&A Expenses | $5,117 | $4,342 | $5,161 | $6,003 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $327 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $34,105 | $28,429 | $25,086 | $38,329 |
| Operating Income | -$34,105 | -$28,429 | -$25,086 | -$38,329 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,828 | $3,855 | $4,087 | $4,937 |
| Pre-Tax Income | -$30,277 | -$24,574 | -$20,999 | -$33,392 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30,277 | -$24,574 | -$20,999 | -$33,392 |
| % Margin | – | – | – | – |
| EPS | -0.69 | -0.58 | -0.5 | -1.54 |
| % Growth | -19% | -16% | 67.5% | – |
| EPS Diluted | -0.69 | -0.58 | -0.5 | -1.54 |
| Weighted Avg Shares Out | 44,067 | 42,233 | 41,680 | 16,789 |
| Weighted Avg Shares Out Dil | 44,067 | 42,233 | 41,680 | 16,789 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,832 | $3,857 | $4,092 | $4,533 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $20 | $19 | $16 | $18 |
| EBITDA | -$30,257 | -$24,555 | -$20,983 | -$37,438 |
| % Margin | – | – | – | – |